$OTLK 8-K SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
18 Sep 2026	8-K: Other Events On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.
27 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
14 Aug 2026	8-K: Other Events
14 Aug 2026	8-K: Results of Operations and Financial Condition
12 Aug 2026	8-K: Results of Operations and Financial Condition; Other Events
24 Jul 2026	8-K: Other Events
24 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
16 Jul 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
26 Jun 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
16 Jun 2026	8-K: Other Events
01 Jun 2026	8-K: Other Events
29 May 2026	8-K: Other Events
28 May 2026	8-K: Other Events
26 May 2026	8-K: Other Events
18 May 2026	8-K: Results of Operations and Financial Condition
13 May 2026	8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
23 Apr 2026	8-K: Unregistered Sales of Equity Securities; Other Events
21 Apr 2026	8-K: Other Events
07 Apr 2026	8-K: Other Events

Comments